Dermobacter

Quick links to important sections

Dermobacter

Method of action: Disinfectant

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dermobacter

Property Description
Active ingredients Benzalkonium chloride, Chlorhexidine digluconate
Form Solution for cutaneous application (often foaming)
Pharmacological class Topical Antiseptic and Disinfectant
Common use Local hygienic management and decontamination
Origin Synthetic

What is the Pharmacological Class and Type of Dermobacter?

Dermobacter is a synthetic medicinal preparation classified as a Topical Antiseptic and Disinfectant, designated strictly for external use on the skin and mucous membranes. It is defined as a combination product, relying on the simultaneous action of two distinct antimicrobial agents to achieve its intended effect. This dual-agent strategy is clinically recognized for offering a potentially broader and more robust antimicrobial scope than single-agent alternatives. The preparation's high-level classification establishes its primary role as a surface hygiene product, suitable for conditions requiring general, localized decontamination.

What is the Composition and Form of Dermobacter Solution?

The active ingredients in the preparation are Benzalkonium chloride and Chlorhexidine digluconate. Dermobacter is supplied as an aqueous solution for cutaneous application, a distinctive form that generates a cleansing foam upon application. The composition deliberately pairs Benzalkonium chloride (a quaternary ammonium compound) with Chlorhexidine digluconate (a biguanide). This combination is often favored for its efficacy in rapidly reducing micro-organisms in a cleansing base, offering an alternative to harsh, alcohol-based solutions.

What is the General Purpose of Dermobacter?

The general purpose of using Dermobacter is to achieve essential decontamination and local hygienic management of the skin and mucous membranes. This is accomplished through its broad-spectrum bactericidal action, which rapidly reduces the population of harmful micro-organisms on the treated surface. For example, it provides crucial preliminary cleansing for minor skin abrasions or surface cuts. This rapid reduction of the microbial load is fundamental for maintaining surface cleanliness and assisting the natural process of managing minor superficial issues. The overall benefit is the promotion of essential initial surface hygiene.

Regulatory References

  1. Dermobacter Summary of Product Characteristics (SPC)

What side effects are possible with Dermobacter?

Possible Side Effects and Safety Information

The official safety profile for Dermobacter solution, a combination topical antiseptic, is classified by focusing on local application effects, specific population risks, and safety constraints on use. Adverse reactions are primarily categorized as Skin and Subcutaneous Tissue Disorders.


Officially Documented Adverse Reactions

The most commonly observed local adverse reactions noted in regulatory documents include dry skin, a sensation of mucosal dryness, and slight skin irritation, which may appear during the first applications. The possibility of contact dermatitis is also listed. These non-serious local effects are noted to be attenuated by careful rinsing of the treated area.

Serious Adverse Reactions and Systemic Risk

Official labeling documents a risk of chemical burns, which is specifically highlighted for use in newborn babies (neonates), especially preterm infants. Furthermore, the chlorhexidine component carries a risk of anaphylaxis, a severe, life-threatening systemic allergic reaction. The risk of systemic effects from absorption cannot be excluded if the solution is applied to a large surface, damaged skin, mucous membranes, or the skin of premature infants.


Safety Constraints and Special Populations

Special care is required for newborn babies due to the risk of chemical burns. The solution should not be applied to the breasts during the breast-feeding period. A high-level safety constraint in the label requires avoiding the simultaneous or successive use of anionic antiseptics to prevent potential inactivation of the active ingredients. This regulatory framework mandates caution in high-risk scenarios.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information regarding Dermobacter overdose focuses on the risks associated with accidental ingestion and excessive topical use.

Documented Overdose Manifestations

Excessive application of the solution may result in an exacerbation of local undesirable effects, such as dry skin, mucosal dryness sensation, slight skin irritation, and contact dermatitis. While no overdose cases have been formally reported in regulatory summaries, the potential for systemic effects must be considered.

Severe Outcomes and Emergency Actions

Outcome/Risk Required Action (Regulatory Standard)
Accidental Oral Ingestion Seek medical help or contact a Poison Control Center right away (standard guidance for this class of antiseptic agents).
Chemical Burns Requires immediate medical attention, particularly if severe.
Systemic Absorption Risk Close monitoring is required.

Systemic absorption cannot be excluded if the solution is applied to a large surface, damaged skin (such as burns), or under occlusive dressings. Application to the skin of neonates and premature infants poses a specific risk for systemic absorption and local injury, including chemical burns, due to their vulnerable skin barrier and high surface-area-to-weight ratio. Management is typically symptomatic and supportive, as no specific antidote is officially documented.

Therapeutic Uses of Dermobacter

Dermobacter is used for managing localized skin and mucous membrane hygiene. Its therapeutic value supports easing specific surface issues and may assist with managing the risk of microbial contamination.

The solution is commonly used for the adjunctive local treatment and cleansing of superficial skin disorders and issues affecting external mucous membranes that are already infected or may be part of symptomatic management when infection risk is present. Indications may be part of symptomatic management for preliminary cleansing of minor superficial trauma, localized hygienic management of affected skin, and supportive care for conditions involving microbial presence.

The solution is applied when appropriate in situations that benefit from decontamination. The application of this product assists with surface decontamination, helping manage the presence of harmful micro-organisms. The preparation supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load associated with surface contamination.


Quick Fact: Relief for Microbial Contamination

Quick Fact: Relief for Microbial Contamination may be part of symptomatic management through the promotion of appropriate local hygiene. This may assist with preventing the colonization of exposed tissues and provides supportive relief for managing minor surface injuries.

Regulatory References

  1. French Public Database of Medicines

Eligibility and Restrictions for Use

Who Can and Cannot Use Dermobacter?

This section describes official population eligibility information as defined by regulatory documents.


Eligibility Scope

Classification Populations Rule Basis
Contraindicated Individuals with known Hypersensitivity to Chlorhexidine, Benzalkonium chloride, or any component. Absolute prohibition due to allergy risk.
Prohibited Use Application to the eyes (ophthalmic use) or the external auditory canal (eardrum perforation). Site-specific prohibition due to toxicity risk.
Restricted Use Pregnant individuals, Lactating individuals, and Neonates/Premature Infants. Use is not recommended or requires special caution due to increased absorption potential or risk of infant ingestion (application to the breasts is prohibited).
Permitted Use Adults and Adolescents. Generally allowed for the labeled cutaneous and external mucous membrane applications.

Age-Related and Conditional Rules

  • Infants and Young Children: Some formulations may be contraindicated for application to the face and head in children under 30 months of age. Use in all infants requires caution.
  • Organ Impairment: No specific restrictions are typically listed for patients with renal or hepatic impairment.

Connection to the overall eligibility profile: The regulatory profile strictly governs use through absolute contraindications for known allergies and specific anatomical site prohibitions. Use in vulnerable populations, such as pregnant women and infants, is heavily restricted, classifying them as not recommended or requiring special caution. This framework establishes clear exclusionary rules to minimize the risk of localized harm or systemic exposure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Dermobacter (Benzalkonium chloride and Chlorhexidine digluconate) is defined by chemical and physical incompatibilities due to its topical, cationic nature, not systemic metabolic interactions. The regulatory documentation notes that percutaneous absorption of the active ingredients is very slight, precluding clinically significant drug–drug interactions involving CYP enzymes or drug transporters.


Official Regulatory Interaction Profile

Property Officially Documented Restriction
Interacting Product Class Anionic Antiseptics and Agents
Mechanistic Basis Chemical Inactivation: The cationic agents are chemically reduced by anionic substances, leading to diminished local activity.
Timing-Based Restriction Simultaneous or successive use with anionic antiseptics must be avoided.
Product Incompatibility Contact with hypochlorite bleaches (common household products) is documented to result in brown staining of materials previously treated with the solution.

Regulatory Summary of Interaction Constraint

This profile is classified by regulatory authorities as a combination not recommended due to the resulting reduction in efficacy, which stems from the local chemical reaction. The primary constraint is strictly procedural, requiring the avoidance of co-application or sequential application with anionic agents, including soaps, to preserve the intended antiseptic action. No population-specific interaction considerations related to hepatic or renal function are documented.

Mechanism of Action

The mechanism of Dermobacter relies on the synergistic, localized action of its two active ingredients—Benzalkonium chloride and Chlorhexidine digluconate—to facilitate profound microbial load reduction on the treated surface.


Dual-Action Destruction of Bacterial Cell Structure

This mechanism begins with the physical destabilization of the microbial cell membrane. The two cationic agents target and bind to the negatively charged phospholipids and proteins of the cell membrane. This binding causes the membrane to lose its selective permeability, initiating the bactericidal cascade and resulting in the immediate leakage of vital intracellular components.


Irreversible Intracellular Coagulation and Metabolic Halt

Following the breach of the membrane, the agents rapidly penetrate the cell interior and cause widespread coagulation and denaturation of macromolecules, including essential metabolic enzymes and nucleic acids. This permanent destruction of both the cell's physical structure and its internal function is the mechanism that facilitates a substantial reduction of the viable microbial load. Additionally, the Chlorhexidine component binds strongly to surface skin proteins, establishing a residual depot that facilitates prolonged localized microbial suppression post-application.

Dosage and Administration Information

The administration of Dermobacter solution is designated for topical use on both the skin and external mucous membranes.

Administration Scope and Dosage Modalities

Feature Usage Guideline
Route of Administration Topical (External cutaneous application and external mucous membranes).
Dosing Schedule Used pure for application to the skin; used diluted at 1/10^th for external mucous membranes.
Frequency and Duration Applied once or twice a day over a course typically lasting 7 to 10 days.

Preparation and Procedural Constraints

Specific rules apply to the handling of the solution during administration:

  • Preparation Requirement: When dilution is necessary for mucous membranes, the resulting 1/10^th solution must be prepared immediately before use (extemporaneously) and must not be stored.
  • Post-Application Step: The administration, whether pure or diluted, must always be followed by careful rinsing of the treated area.
  • Incompatibility Constraint: The product must not be used simultaneously or successively with other local antiseptics or soaps, unless the surface is thoroughly rinsed after the use of soap.

These instructions define the approach to using the solution, covering the preparation and application procedure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dermobacter

Evidence for Preoperative Skin Cleansing and Antisepsis

Dermobacter was studied for its use in cleansing the skin prior to surgical procedures. Research examined this use primarily through Randomized Controlled Trials (RCTs) and comparative clinical studies. These studies typically monitored outcomes such as measurements of skin microbes and whether the use of the solution was associated with changes in the rates of surgical site infection (SSI) in the weeks after the procedure. The populations observed in these studies generally included adult and pediatric patients undergoing various planned surgeries.

Studies report how symptoms evolved in the observed populations by measuring the changes in bacteria on the skin after use. Some trials reported measurements of changes in bacterial counts on the skin surface immediately following application. Furthermore, certain hospital settings have described patterns in the incidence of SSI for patient groups where Dermobacter was observed in the preoperative protocol. Findings describe patterns observed in the studies over the intermediate-term, as patients were typically tracked for infection incidence for up to about 30 days post-procedure.

Evidence for Wound Cleansing and Local Adjunctive Treatment

For the cleaning of minor wounds and localized skin issues, the evidence was evaluated in different types of research, including observational clinical series and laboratory in vitro studies. Studies explored how the product was associated with changes in the bacterial load within the wound area. In laboratory settings, the in vitro studies reported measurements of the solution's action against germs.

Comparative evidence is lacking from high-quality trials that directly compare Dermobacter to other standardized wound care practices. Evidence quality varies across studies due to the wide range of wound types and severities that have been reported. Data for certain groups remain insufficient, particularly for patients with complex conditions.

What Research Gaps and Uncertainty Remain

While various studies have explored the use of Dermobacter, evidence is limited in several key areas. Certainty remains low for long-term use, as follow-up durations were limited in many of the primary studies. Comparative evidence is lacking in some areas, and findings were mixed regarding consistency of effects in diverse clinical settings, meaning subgroup findings are uncertain. Research is ongoing to provide better context, but the current body of evidence contributes to understanding what has been observed—and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Dermobacter (FAQ)

Q: What is the difference between Dermobacter and a regular over-the-counter soap?

A: Dermobacter is classified as an antiseptic and disinfectant preparation, distinct from regular soap. Official documentation notes that the product is not recommended for simultaneous or successive use with other soaps or anionic antiseptics, as this constraint is in place because using them together could chemically reduce the intended antiseptic action.


Q: Can Dermobacter be used for fungal skin issues?

A: Regulatory documents describe Dermobacter as a broad-spectrum bactericidal antiseptic. Official information indicates that, in laboratory studies (in vitro), the active ingredients demonstrated action against certain fungi, such as Candida Albicans. The primary indications, however, focus on bacterial load reduction.


Q: How long can Dermobacter be used before needing a break?

A: Regulatory documents state that the typical course of application for this solution lasts 7 to 10 days. Research summaries note that follow-up durations were limited in many of the primary studies, meaning certainty remains low regarding the safety of use over a long-term period.


Q: How does Dermobacter compare to chlorhexidine products?

A: Dermobacter is officially defined as a combination product that uses two active ingredients for its effect. This dual-agent strategy relies on the simultaneous action of both Chlorhexidine digluconate (a biguanide) and Benzalkonium chloride (a quaternary ammonium compound) to achieve its antimicrobial action.


Q: Can Dermobacter be used on broken skin or open wounds?

A: Official warnings note that the risk of systemic effects (absorption into the body) cannot be excluded if the solution is applied to a large surface area or to damaged skin, such as severe abrasions or burns. The product is designated for external use on the skin and external mucous membranes. The warning against use on large or damaged skin surfaces is primarily to minimize the risk of absorption.


Q: Can Dermobacter be used with medicated shampoos?

A: Official documentation states that the simultaneous or successive use of the product with other local antiseptics or soaps should be avoided. This procedural constraint is to prevent chemical reactions that could diminish the intended effect of the active ingredients.


Q: Has Dermobacter been studied in older adult populations?

A: Regulatory research overviews indicate that studies generally included adult and pediatric patients. However, the regulatory summaries state that specific subgroup findings for older adult or geriatric populations are often uncertain or mixed when comparing results from diverse clinical settings.


Q: Why do some people call Dermobacter an 'antiseptic' and others a 'wash'?

A: Official pharmacological documents classify the product as a Topical Antiseptic and Disinfectant. The product is supplied as an aqueous solution that generates a foam. As it is indicated for the cleansing and adjuvant treatment of skin and mucous membranes, its function aligns with common perceptions of a hygienic wash.


Q: Can Dermobacter change the color of my skin or clothing?

A: Official documents report that the product's active ingredients can react with hypochlorite bleaches (found in many household cleaning products) which may result in brown staining of materials previously treated with the solution. Skin staining is not listed as a documented adverse reaction.


Q: What is the difference between Dermobacter solution and Dermobacter foam?

A: Dermobacter is supplied as a single preparation: an aqueous solution for cutaneous application. Due to the excipients (non-active ingredients) in the formula, this solution is designed to generate a cleansing foam upon use, making the application process easier.


Q: Does Dermobacter contain alcohol or fragrances?

A: The official list of non-active ingredients, or excipients, does not list ethanol, isopropyl alcohol, or added fragrances as components of the formulation for this product.


Q: What kind of studies have been done on Dermobacter's effectiveness?

A: The evidence supporting the use of this product has been gathered from multiple types of research, including Randomized Controlled Trials (RCTs), comparative clinical studies, observational clinical series, and laboratory in vitro studies.


Q: Can Dermobacter be used if I am pregnant?

A: Use during pregnancy is listed as a restricted use in official documents and is generally not recommended. This caution is due to the potential risk of systemic effects from slight absorption through the skin.


Q: Are there different strengths or concentrations of Dermobacter?

A: The product is supplied as a single formulation. It contains a fixed concentration of its two active ingredients, Benzalkonium chloride and Chlorhexidine digluconate, which remains the same across the standard solution preparation.


Q: Is Dermobacter known to cause any long-term skin changes?

A: Current regulatory research summaries note that certainty remains low for the long-term safety of the product. This uncertainty is primarily because the follow-up durations for patients in the primary studies were limited.


Q: How long do the effects of Dermobacter last after rinsing?

A: Official information indicates that the Chlorhexidine component binds strongly to the skin's surface proteins. This binding creates a residual depot that is described as facilitating localized microbial suppression after application and rinsing, though a specific duration is not provided in the regulatory documents.


Q: Does Dermobacter kill all types of bacteria?

A: The product is described as a broad-spectrum bactericidal antiseptic. In laboratory studies, it has been shown to be active against both Gram-positive and Gram-negative germs.


Q: Can Dermobacter cause dryness or irritation over time?

A: The most commonly observed local adverse reactions listed are dry skin, sensation of mucosal dryness, and slight skin irritation. These effects may appear during the first applications but are generally lessened by careful rinsing of the treated area.


Q: What are the non-active ingredients in Dermobacter?

A: The other ingredients (excipients) listed in the official product leaflet are betaine cocoalkyldimethyl 30% solution, poloxamer 188, hydroxyethylcellulose, citric acid monohydrate, sodium citrate, and purified water.


Q: What is the recommended duration of a typical course of Dermobacter use?

A: According to regulatory posology documents, the typical course of application for the solution is applied once or twice a day over a course generally lasting 7 to 10 days.


Q: Why is Dermobacter sometimes prescribed before certain medical procedures?

A: The research evidence explicitly details studies conducted on the product's use in cleansing the skin prior to surgical procedures. These studies monitored outcomes such as the reduction of skin microbes and the association with changes in surgical site infection (SSI) rates.


Q: Does Dermobacter help with body odor?

A: The product's purpose is to achieve local hygienic management through its broad-spectrum bactericidal action. The reduction of micro-organisms on the surface of the skin is the documented effect.


Q: Is Dermobacter known to be affected by herbal supplements?

A: The official interaction profile is defined by local chemical incompatibilities (like with soaps). Regulatory documentation notes that percutaneous absorption of the active ingredients is very slight, which would preclude clinically significant systemic drug–drug interactions, such as those that may occur with oral herbal supplements.


Q: What is the official classification of Dermobacter (e.g., disinfectant, antiseptic, drug)?

A: Dermobacter is officially classified as a synthetic medicinal preparation and a Topical Antiseptic and Disinfectant. It is assigned the anatomical therapeutic chemical (ATC) code D08AC52.

How should Dermobacter be stored and disposed of?

How to Store and Dispose of Dermobacter Solution for Cutaneous Application

The storage and disposal of Dermobacter solution must strictly follow official regulatory requirements.


Storage Conditions

  • Temperature: The solution must be stored at a temperature that does not exceed 25 C.
  • Dilution: Any diluted solution must be prepared immediately before use and must not be stored.
  • Child Safety: The medicine must be kept out of the sight and reach of children.
  • Expiry: The product must not be used after the expiry date printed on the bottle.

Disposal Instructions

Expired or unused solution must not be thrown away via wastewater or common household waste.

Patients should consult a pharmacist for guidance on the proper method for discarding any medicines no longer needed. This adherence to specific disposal procedures helps to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dermobacter found in:

A-Z Index: